Paul Meyvisch

3.0k total citations · 1 hit paper
30 papers, 1.6k citations indexed

About

Paul Meyvisch is a scholar working on Epidemiology, Hepatology and Statistics and Probability. According to data from OpenAlex, Paul Meyvisch has authored 30 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 8 papers in Hepatology and 8 papers in Statistics and Probability. Recurrent topics in Paul Meyvisch's work include Hepatitis C virus research (8 papers), Statistical Methods in Clinical Trials (7 papers) and Statistical Methods and Bayesian Inference (5 papers). Paul Meyvisch is often cited by papers focused on Hepatitis C virus research (8 papers), Statistical Methods in Clinical Trials (7 papers) and Statistical Methods and Bayesian Inference (5 papers). Paul Meyvisch collaborates with scholars based in Belgium, United States and Netherlands. Paul Meyvisch's co-authors include Nacer Lounis, Koen Andries, Alexander S. Pym, Tine De Marez, Martin P. Grobusch, Andreas H. Diacon, Brian Dannemann, Nyasha Bakare, Rolf P. G. van Heeswijk and I. А. Vаsilyevа and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Paul Meyvisch

27 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

2014 505 citations Andreas H. Diacon, Alexander S. Pym et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Paul Meyvisch

Since Specialization

Citations

This map shows the geographic impact of Paul Meyvisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Meyvisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Meyvisch more than expected).

Fields of papers citing papers by Paul Meyvisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Meyvisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Meyvisch. The network helps show where Paul Meyvisch may publish in the future.

Co-authorship network of co-authors of Paul Meyvisch

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Meyvisch. A scholar is included among the top collaborators of Paul Meyvisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Meyvisch. Paul Meyvisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On sample size calculation in drug interaction trials 2024 ·Pharmaceutical Statistics ·Paul Meyvisch, Mitra Ebrahimpoor	0
2	Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy 2020 ·Leen Slaets, Filip De Ridder, Oliver Lenz, Maria Beumont, Paul Meyvisch, Thierry Verbinnen	3
3	Univariate Versus Multivariate Surrogates in the Single-Trial Setting 2019 ·Statistics in Biopharmaceutical Research ·Wim Van der Elst, Ariel Alonso, Helena Geys, Paul Meyvisch, Luc Bijnens, (unknown), Geert Molenberghs	8
4	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design 2019 ·Advances in Therapy ·Eva Santermans, Paul Ford, Michael Kreuter, Nadia Verbruggen, Paul Meyvisch, Wim Wuyts, Kevin K. Brown, David J. Lederer, Adam J. Byrne, Philip L. Molyneaux, (unknown), Catharina C. Moor, Toby M. Maher, Marlies Wijsenbeek	5
5	Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial 2018 ·PLoS ONE ·Paul Meyvisch, (unknown), Koen Andries, Nacer Lounis, (unknown), Brian Dannemann, An Vandebosch, Wim Van der Elst, Geert Molenberghs, Ariel Alonso	10
6	Evaluation of the Addition of Firth’s Penalty Term to the Bradley-Terry Likelihood 2016 ·Journal of Modern Applied Statistical Methods ·Paul Meyvisch	1
7	Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis 2015 ·European Respiratory Journal ·Alexander S. Pym, Andreas H. Diacon, Shenjie Tang, Francesca Conradie, Manfred Danilovitš, Charoen Chuchottaworn, I. А. Vаsilyevа, Koen Andries, Nyasha Bakare, Tine De Marez, (unknown), Nacer Lounis, Paul Meyvisch, Ben Van Baelen, Rolf P. G. van Heeswijk, Brian Dannemann	226
8	Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline breakdown → 2014 ·New England Journal of Medicine ·Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, (unknown), Eduardo Gotuzzo, I. А. Vаsilyevа, Vaira Leimane, Koen Andries, Nyasha Bakare, Tine De Marez, (unknown), Nacer Lounis, Paul Meyvisch, Els De Paepe, Rolf P. G. van Heeswijk, Brian Dannemann	505
9	Safety and Pharmacokinetics of the HIV-1 Protease Inhibitor TMC310911 Coadministered With Ritonavir in Healthy Participants 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Richard M. W. Hoetelmans, Inge Dierynck, (unknown), Paul Meyvisch, (unknown), (unknown), Kenneth Simmen, René Verloes	3
10	Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance 2012 ·Antimicrobial Agents and Chemotherapy ·Andreas H. Diacon, Peter R. Donald, Alexander S. Pym, Martin P. Grobusch, R. F. Patientia, (unknown), Nonkqubela Bantubani, (unknown), Tine De Marez, Rolf van Heeswijk, Nacer Lounis, Paul Meyvisch, Koen Andries, D. F. McNeeley	292
11	Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial 2011 ·Antiviral Therapy ·Michael P. Manns, H. W. Reesink, Thomas Berg, Geoffrey Dusheiko, Robert Flisiak, Patrick Marcellin, Christophe Moreno, Oliver Lenz, Paul Meyvisch, Monika Peeters, Vanitha Sekar, Kenneth Simmen, René Verloes	57
12	1076 EVALUATION OF METABOLIC INTERACTIONS FOR TMC435 VIA CYTOCHROME P450 (CYP) ENZYMES IN HEALTHY VOLUNTEERS 2010 ·Journal of Hepatology ·(unknown), René Verloes, Paul Meyvisch, (unknown), (unknown), Goedele De Smedt	15
13	1075 PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) ANALYSES OF TMC435 IN TREATMENT-NAIVE HEPATITIS C (HCV)-INFECTED PATIENTS IN THE OPERA-1 STUDY 2010 ·Journal of Hepatology ·(unknown), Peter Vis, Oliver Lenz, Paul Meyvisch, Marc Peeters, Goedele De Smedt	4
14	Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients 2009 ·Gastroenterology ·H. W. Reesink, Gregory Fanning, (unknown), Christine J. Weegink, André van Vliet, Gerben van ‘t Klooster, Oliver Lenz, (unknown), (unknown), P. Van Remoortere, Herman de Kock, F. Broeckaert, Paul Meyvisch, (unknown), Kenneth Simmen, René Verloes	123
15	Safety and Antiviral Activity of Tmc435350 in Treatment-name Genotype 1 Hcv-infected Patients 2008 ·Hepatology ·Michael P. Manns, Yves Horsmans, Hendrik W. Reesink, Christophe Moreno, Thomas Berg, Yves Benhamou, Geoffrey Dusheiko, Robert Flisiak, Paul Meyvisch, Oliver Lenz, Kenneth Simmen, René Verloes	3
16	64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY 2008 ·Journal of Hepatology ·Hendrik W. Reesink, René Verloes, (unknown), (unknown), Christine J. Weegink, Gerben van ‘t Klooster, (unknown), (unknown), P. Van Remoortere, Herman de Kock, F. Broeckaert, Gregory Fanning, Paul Meyvisch, (unknown), Kenneth Simmen	16
17	Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures 2008 ·Neurology ·(unknown), E. Andermann, Paul Meyvisch, Frédérick Andermann, William B. Gough, (unknown)	184
18	Levetiracetam Intravenous Infusion as an Alternative to Oral Dosing in Patients with Partial‐Onset Seizures 2007 ·Epilepsia ·Michel Baulac, Martin J. Brodie, Christian E. Elger, Karsten Krakow, Armel Stockis, Paul Meyvisch, Ursula Falter	40
19	Microbiology of the middle meatus in children requiring adenotonsillectomy 1999 ·The Journal of Laryngology & Otology ·Frans Gordts, (unknown), Denis Piérard, Paul Meyvisch, Péter Clement	6
20	Intravenous Nitrates for Pharmacological Stimulation During Head‐Up Tilt Testing in Patients with Suspected Vasovagal Syncope and Healthy Controls 1999 ·Pacing and Clinical Electrophysiology ·(unknown), Paul Dendale, (unknown), Paul Meyvisch, Leonard Kaufman, (unknown), Pierre Block	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact